1-3 of 3
Zenta Walther
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang-Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2123–2130.
https://doi.org/10.1158/1078-0432.CCR-22-3497
Published: 01 June 2023
View article titled, Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Open the PDF for Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3752–3760.
https://doi.org/10.1158/1078-0432.CCR-22-0741
Published: 01 September 2022
View article titled, Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403)
Open the PDF for Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403) in another window
Includes: Supplementary data
Journal Articles

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Anna Truini, Jacqueline H. Starrett, Tyler Stewart, Kumar Ashtekar, Zenta Walther, Anna Wurtz, David Lu, Jin H. Park, Michelle DeVeaux, Xiaoling Song, Scott Gettinger, Daniel Zelterman, Mark A. Lemmon, Sarah B. Goldberg, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6382–6391.
https://doi.org/10.1158/1078-0432.CCR-19-0780
Published: 01 November 2019
View article titled, The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Open the PDF for The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma in another window
Includes: Supplementary data